

THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of Sheriff et al.

Application No.: 10/572,875

Filed: March 22, 2006

For: COMPOUNDS FOR NEUTRALIZING THE EFFECTS OF SECRETED PLA2 IIA

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

This Supplemental Information Disclosure Statement is submitted to correct a typographical error on the Form PTO-1449 which accompanied the Information Disclosure Statement filed May 2, 2006. Attached is a corrected Form PTO-1449 wherein it will be noted that the last name of the author of the second listed non-patent publication has been corrected to read "Thwin, Maung-Maung". Copies of the cited references accompanied the Information Disclosure Statement filed on May 2, 2006.

This paper is being filed before first action on the merits or within 3 months of the application filing date or date of entry into the national stage. Accordingly, no fee is required. Should a fee be required, please charge it to Deposit Account No. 06-1358.

Respectfully submitted,

TA COPPOSITION A ALVERY

By:

William E. Playe

Reg. No. 31,409

400 Seventh Street, N.W. Washington, DC 20004 Tel. (202) 638-6666 Fax (202) 393-5350 Date: May 19, 2006

WEP/ihr

R:\rthomas\wep\2006\May\P71167US0 Suppl. IDS.wpd

		Yau	1 8 5000 R			
Sheet 1	of 1	\ .	<i>₹</i> /			
FORM PTO 1449 (modified 7 & TRACE)						et - P71167US0
U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE					Application No 10/572,875	
LIST OF REFERENCES CITED BY APPLICANT(S) (Use several sheets if necessary)					Applicant	- Sheriff et al.
	(coc coveral enecte if necessary)					- March 22, 2006
			U.S	S. PATENT DOCUMENTS		· · · · · · · · · · · · · · · · · · ·
Examiner [†] Ref. #			Document No.		Date	Patentee/Applicant
						<u> </u>
_						
FOREIGN PATENT DOCUMENTS						
		Country	Document No.	Translation Abstract	Date	Patentee
	<u> </u>					
	ļ			0 0		
	T		NO.	N-PATENT DOCUMENTS		110
Examiner [†]	Ref. #	Author (in CAPITAL LETTERS), Title, Book or Periodical, Volume, Date, Pages)				
		Hundley, T.R. et al., "Characteristics of Arachidonic Acid Generation in Human Basophils: Relationship Betwee Effects of Inhibitors of Secretory Phospholipase A ₂ Activity and Leukotriene C ₄ Release," The Journal of Pharmacology and Experimental Therapeutics, Mar 1998, Vol. 284, No. 3, pgs. 847-857				
	Thwin, Maung-Maung et al., "Functional site of endogenous phospholipase A ₂ inhibitor from python serum," European Journal of Biochemistry/Febs. Jan 2002, vol. 269, 719-727 Furue, Shingo, MS. et al., "Therapeutic time-window of a group IIA phospholipase A ₂ inhibitor in rabbit acute lung injury: Correlation with lung surfactant protection," Critical Care Medicine, April 2001, vol. 29, no. 4, pgs. 719-727					
		Niessen, Hans W.M. et al., "Type II secretory phospholipase A2 in cardiovascular disease: a mediator in atherosclerosis and ischemic damage to cardiomyocytes?" Cardiovascular Research, 15 Oct. 2003, vol. 60, no. 1, 4 September 2003, pgs. 68-77				
	Graff, Jeremy R. et al., "Expression of Group IIa Secretory Phospholipase A2 Increases with Prostate Tumor Grac Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, Dec. 2001, vol. no. 12, December 2001, pgs. 3857-3861 Bidgood, Matthew J. et al., "Type IIA Secretory Phospholipase A2 Up-Regulates Cyclooxygenase-2 and Amplifies Cytokine-Mediated Prostaglandin Production in Human Rheumatoid Synoviocytes ¹ " Journal of Immunology, September 1, 2000, vol. 165, no. 5, pgs. 2790-2797					
	Menschikowski, M. et al. "Expression of Secretory Group IIA Phospholipase A ₂ in Relation to the Presence of Microbial Agents, Macrophage Infiltrates, and Transcripts of Proinflammatory Cytokines in Human Aortic Tissues, Arterioscler Thromb Vasc. Biol, pgs. 751-762 June 16, 1999					
Examiner Signature	gnature					Date Considered

[†]Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.